Clinical Trial

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients with metastatic Triple Nagative Breast Cancer who have received at least one, and no more than two, prior standard of care chemotherapy regimens
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-09-25; most recent amendment 2025-08-21.
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT06616987
Lead Sponsor Yeon Hee Park
Conditions Breast Cancer Metastatic
Enrollment 40 participants
Start Date 2025-07-03
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-28